HTB

Antiretrovirals

HIV pipeline 2018: full version

Bictegravir/FTC/TAF (Biktarvy) approved in Europe

New contraindication against using darunavir/cobicistat during pregnancy

China approves albuvirtide: a once-weekly injectable entry inhibitor

Single dose PRO140 mAb reduces viral load by 0.5 log copies/mL in people with multidrug resistance

EMA approves dolutegravir/rilpivirine (Juluca) in Europe as dual-therapy HIV switch option

Meta-analysis of TAF vs TDF in boosted vs unboosted regimens

Meta-analysis of dolutegravir in naive, experienced and switch studies

Drug cost savings from routine use of generic ARVs: safety and efficacy in practice

Ibalizumab phase 3 results and susceptibility to drug-resistant HIV

Bictegravir at CROI 2018: switching studies and drug resistance analyses

FDA approves ibalizumab in the US to treat multidrug HIV resistance

FDA grants tentative approval to first DTG/FTC/TAF FDC

Bictegravir approved in the US in new integrase-inhibitor based FDC (Biktarvy)

US approve a lower-dose efavirenz (400 mg) based generic FDC (Simfi Lo)

ViiV announces phase 3 study switching to dolutegravir/3TC dual therapy from TAF-containing ART

US darunavir label updated: drug interactions and pregnancy

Doravirine FDC submitted to FDA in US: decision expected October 2018

FDA approves raltegravir for newborns

Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results

D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed

ABX464 nudges viral reservoir but not time to viral rebound

Long-acting ART for children is a deferred priority despite achievable dosing

Coformulated dolutegravir plus rilpivirine approved in US (Juluca)

Darunavir-based single pill FDC approved in EU (Symtuza)

Dual therapy with darunavir/r plus lamivudine as first-line ART

Dual therapy with dolutegravir plus lamivudine as first-line ART

Once-daily raltegravir: 96-week results from the ONCEMRK study

Gilead uses voucher to speed FDA review of bictegravir

HIV pipeline drugs: IAS 2017 update

Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study

Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF

Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART

Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results

Reduced-dose darunavir is safe and effective in switch study

MK-8591: further compelling early results for both treatment and prevention

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

First dolutegravir-based FDC gets FDA tentative approval

FDA grant priority review for ibalizumab

Introduction to HIV pipeline 2017

HIV pipeline 2017: full version

HIV pipeline 2017: summary version

HIV pipeline 2017: Update from IAS Paris

Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

Dolutegravir pharmacokinetics in pregnancy

High rates of of undocumented efavirenz-related side effects in Uganda

Increased risk of ART failure after low-level viraemia in a large South African cohort

Option B+ Malawi

Dolutegravir/rilpivirine submitted to EMA and FDA as oral two-drug maintenance combination

Bictegravir/FTC/TAF: new once-daily integrase-based FDC submitted to US FDA

FDA updates cobicistat and Stribild labels: interactions with systemic, inhaled, nasal and ophthalmic corticosteriods

Drop in HIV incidence in gay men: frequent testing, early ART and PrEP

Prompt/early ART: Dean Street pilot project reports 75% uptake

Other selections and webcasts

Dose reduction potential of nanoparticle ARV formulations confirmed in humans

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

Tenofovir alafenamide exposure is modestly higher in children than adults

Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence

Increased risk of IRIS with integrase inhibitors reported in two studies

Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor

New NNRTI doravirine is non-inferior to darunavir/r in phase 3 treatment naive study

NRTI GS-9131 resurfaces at CROI 2017: in vitro sensitivity to nuke-resistant HIV

Post navigation